Coherus Oncology, Inc. — Director's Dealing 2014

Nov 12, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Coherus BioSciences, Inc. (CHRS)
CIK: 0001512762
Period of Report: 2014-11-12

Reporting Person: HEALY JAMES (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-11-12	Common Stock, $0.0001 par value	C	47	—	Acquired	47	Direct
2014-11-12	Common Stock, $0.0001 par value	C	1846890	—	Acquired	1981863	Indirect
2014-11-12	Common Stock, $0.0001 par value	C	149970	—	Acquired	2131833	Indirect
2014-11-12	Common Stock, $0.0001 par value	P	425926	$13.50	Acquired	2557759	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-11-12	Series B Preferred Stock	$	C	47	Disposed		Common Stock (47)	Direct
2014-11-12	Series B Preferred Stock	$	C	1846890	Disposed		Common Stock (1846890)	Indirect
2014-11-12	Series C Preferred Stock	$	C	149970	Disposed		Common Stock (149970)	Indirect

Footnotes

F1: The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis upon the closing of Issuer's initial public offering.

F2: The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners VII, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners VII, L.P.

F3: Sofinnova Venture Partners VII, L.P. purchased an additional 425,926 shares of Issuer's Common Stock in connection with the IPO at the offering price of $13.50 per share.

F4: The Series B Preferred Stock and Series C Preferred Stock have no expiration date.